Hepatitis News:
August 2007
Numerous
Factors Affect Success Of Interferon Treatment For Hepatitis C
"A new study on predicting outcomes of standard treatment for
hepatitis C virus (HCV) infection found that a number of factors impacted
responses, including the form of the interferon given. However, for some
genotypes of the disease, few of these factors play a role."
Peregrine Pharmaceuticals
Initiates Bavituximab Clinical Trial In HCV Patients Co-Infected With HIV
"Peregrine Pharmaceuticals, Inc., a clinical stage
biopharmaceutical company developing monoclonal antibodies for the
treatment of cancer and hepatitis C virus (HCV) infection, today announced
initiation of patient enrolment in a study of bavituximab in patients
co-infected with HCV and the human immunodeficiency virus (HIV)."
Abbott
Announces Approval of First Fully-Automated Blood Screening Test for
Hepatitis C Antibodies
ABBOTT PARK, Ill., July 12 /PRNewswire-FirstCall/ "Abbott
announced today it received approval from the U.S. Food and Drug
Administration for its ABBOTT PRISM(R) HCV test. This test can be used by
laboratory technicians to screen individual donations of blood and plasma
for antibodies to hepatitis C (HCV)."
Idenix
Study of Hep C Drug Put on Hold
CAMBRIDGE, Mass., July 13 (UPI) - "Idenix Pharmaceuticals said
Friday its studies of potential hepatitis C drug valopicitabine have been
placed on clinical hold in the United States. Following discussions with
the Food and Drug Administration, the hold was placed on the company's
development program due to the "overall risk/benefit profile observed
to date in clinical testing," Idenix said in a statement issued
Friday."
Pharmasset
And Roche Initiate Studies To Advance R7128 For HCV
"Pharmasset, Inc. announces the start of long-term chronic
toxicology studies in two animal species as part of their collaboration
with Roche for the development of R7128 for the treatment of hepatitis C
virus (HCV). R7128 is currently being evaluated in a Phase 1 clinical
trial."
Hep-Outbreak
Probers Eye Double Dip Syringes
July 1, 2007 - "Health investigators are looking into whether
an anesthesiologist suspected of spreading hepatitis infections tainted
batches of medication by "double dipping" syringes into vials
used for multiple patients, The Post has learned. In a widening probe,
officials are also investigating whether other doctors may have used such
sloppy methods - or cut corners on safety to lower costs, sources
said."
Hepatitis
C: An Epidemic Bigger Than HIV
"Conditions such as HIV are known as epidemics worldwide, but Dr.
Allen Reuben said there is another disease that's an even bigger problem
in the United States. Reuben, a consultant in infectious diseases for the
Medical Center of McKinney, said about 2 percent of the population in the
United States is infected with Hepatitis C."
Patient
Alert After Hep C Scare [Australia]
"Thousands of patients of a Sydney doctor are being urged to be
tested for blood-borne viruses, including HIV, after three women
contracted hepatitis C as a result of poor infection control at the
eastern suburbs clinic. In March this year, it was revealed that the three
women - who had visited Daniel Hameiri's general practice clinic for
mineral or vitamin injections - had been diagnosed with hepatitis C. The
clinic in upmarket Double Bay was closed and an investigation
launched."
Music
CD To Reduce Hep C Infection [UK]
"The Department of Health (DH) has launched a music CD in the
hope of raising hepatitis C awareness among the South Asian community. The
CD, initiated as a part of the DH "FaCe It" campaign, mixes
music from popular Asian artists with advice from healthcare
professionals."
The
Easy Way The Government Can Reduce AIDS And Hep C
"We all know that AIDS has become a scourge among black and
Latina women. 64% of American women with AIDS come from the 13% who are
African-American. AIDS is the leading cause of death for black women age
24 - 34 years."
School
Nurses Should Act On Human Bites
WASHINGTON, July 25 - "U.S. school nurses are being urged to
take a proactive stance concerning human bites - especially against the
risk of hepatitis B and C. Bite victims are usually concerned about HIV
transmission, but epidemiological data show the transmission rate for HIV
from saliva is insignificant, according to a paper in The Journal of
School Nursing."
OctoPlus
Announces Promising Results for Locteron Phase IIa Clinical Study
LEIDEN, The Netherlands, July 26, 2007- "OctoPlus N.V., the drug
delivery and development company, announces today positive initial results
of the ongoing SELECT-1 Phase IIa study with its lead product Locteron(TM)
, a controlled release interferon alfa for the treatment of chronic
hepatitis C (HCV)."
Development
Discontinued For ANA975, An Early Stage Compound For Treatment Of
Hepatitis C Virus Infection
"Anadys Pharmaceuticals, Inc. today announced that it and
Novartis have decided to discontinue the development of ANA975, a phase 1b
compound for the treatment of hepatitis C virus (HCV) infection. The
parties have determined that the results received to date from the ongoing
13 week toxicology study together with the results observed in the
previous 13 week toxicology study do not support further clinical
evaluation of chronic daily dosing of ANA975 in hepatitis C
patients."
clinical trials, cohort studies, and pilot studies
The
epidemiology of hepatitis C infection in the United States. Rustgi VK, J
Gastroenterol. 2007 Jul;42(7):513-21. Epub 2007 Jul 25.
Complexity
of the HVR-1 quasispecies and disease activity in patients with hepatitis
C. Kumagai N, et al. Eur J Clin Invest. 2007 Jul;37(7):566-72
Natural
History and Clinical Impact of Cryoglobulins in Chronic Hepatitis C:
10-Year Prospective Study of 343 Patients. Viganò M, et al.
Gastroenterology. 2007 Jul 3; [Epub ahead of print]
Peginterferon
alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. Shiffman
ML, et al. N Engl J Med. 2007 Jul 12;357(2):124-34.
virologic response rate than treatment with the standard
24-week regimen.
Factors
associated with spontaneous clearance of hepatitis C virus among illicit
drug users. Grebely J, et al. Can J Gastroenterol. 2007 Jul;21(7):447-51.
Contrast-enhanced
ultrasound to evaluate the severity of chronic hepatitis C. Ridolfi F, et
al. Dig Liver Dis. 2007 Jul 30; [Epub ahead of print]
Impact
of Asian Race on Response to Combination Therapy With Peginterferon
Alfa-2a and Ribavirin in Chronic Hepatitis C. Missiha S, et al. Am J
Gastroenterol. 2007 Jul 19; [Epub ahead of print]
Efficacy
of ribavirin plus interferon-alpha in patients aged >/=60 years with
chronic hepatitis C. Honda T, et al. J Gastroenterol Hepatol. 2007
Jul;22(7):989-95
Comparison
of low-dose pegylated interferon versus standard high-dose pegylated
interferon in combination with ribavirin in patients with chronic
hepatitis C with genotype 3: An Indian experience. Sood A, et al. J
Gastroenterol Hepatol. 2007 Jul 20; [Epub ahead of print]
Trend
of Depression and the Use of Psychiatric Medications in U.S. Veterans With
Hepatitis C During Interferon-Based Therapy. Jakiche A, et al. Am J
Gastroenterol. 2007 Jul 19; [Epub ahead of print]
py if followed closely by a multidisciplinary team that
includes specialists in hepatitis C and behavioral health.
Efficacy
of low dose long-term interferon monotherapy in aged patients with chronic
hepatitis C genotype 1 and its relation to alpha-fetoprotein: A pilot
study. Nomura H, et al. Hepatol Res. 2007 Jul;37(7):490-7.
Hepatitis-C
Patients Have Reduced Growth Hormone (GH) Secretion Which Improves During
Long-Term Therapy With Pegylated Interferon-alpha. Plöckinger U, et al.
Am J Gastroenterol. 2007 Jul 27; [Epub ahead of print]
Morphine
Inhibits Intrahepatic Interferon- alpha Expression and Enhances Complete
Hepatitis C Virus Replication. Li Y, et al. J Infect Dis. 2007 Sep
1;196(5):719-30. Epub 2007 Jul 18
Glucose
Abnormalities Are an Independent Risk Factor for Nonresponse to Antiviral
Treatment in Chronic Hepatitis C. Lecube A, et al. Am J Gastroenterol.
2007 Jul 7; [Epub ahead of print]
Occupational
risks of blood exposure in the operating room. Fry DE Am Surg. 2007
Jul;73(7):637-46.
Predictors
of response of US veterans to treatment for the hepatitis C virus. Backus
LI, et al. Hepatology. 2007 Jul;46(1):37-47.
basic and applied science, pre-clinical studies
Clinical
Utility of AFP-L3% Measurement in North American Patients with HCV-Related
Cirrhosis. Sterling RK, et al. Am J Gastroenterol. 2007 Jul 7; [Epub ahead
of print]
High
molecular weight form of adiponectin levels of Japanese patients with
chronic hepatitis C virus infection. Furusyo N, et al. Hepatol Res. 2007
Jul 1; [Epub ahead of print]
Tracking
virus-specific CD4+ T cells during and after acute hepatitis C virus
infection. Lucas M, et al PLoS ONE. 2007 Jul 25;2:e649.
Topological
and evolutional relationships between HCV core protein and hepatic lipid
vesicles: Studies in vitro and in conditionally transgenic mice. Chang ML,
et al World J Gastroenterol. 2007 Jul 7;13(25):3472-7.
Relative
contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in
the pathogenesis of altered iron regulation in HCV chronic hepatitis.
Valenti L, et al. Haematologica. 2007 Aug;92(8):1037-42. Epub 2007 Jul 20
Selection
and application of serotypical synthetic peptides derived from hepatitis C
virus NS5A region. Dou XG, et al. Chin Med J (Engl). 2007 Jul
5;120(13):1159-65.
Standardization
of ROC Curve Areas for Diagnostic Evaluation of Liver Fibrosis Markers
Based on Prevalences of Fibrosis Stages. Poynard T, et al. Clin Chem. 2007
Jul 18; [Epub ahead of print]
Both
plasma lysophosphatidic acid and serum autotaxin levels are increased in
chronic hepatitis C. Watanabe N, et al. J Clin Gastroenterol. 2007
Jul;41(6):616-23.
13C-methacetin
breath test as a quantitative liver function test in patients with chronic
hepatitis C infection: continuous automatic molecular correlation
spectroscopy compared to isotopic ratio mass spectrometry. Goetze O, et
al. Aliment Pharmacol Ther. 2007 Jul 15;26(2):305-11.
Poly(A)-binding
protein is differentially required for translation mediated by viral
internal ribosome entry sites. Bradrick SS, et al RNA. 2007 Jul 25; [Epub
ahead of print].
Liver-Targeted
Prodrugs of 2'-C-Methyladenosine for Therapy of Hepatitis C Virus
Infection. Hecker SJ, et. al. J Med Chem. 2007 Aug 9;50(16):3891-3896.
Epub 2007 Jul 18.
Hepatitis
C Virus Stabilizes Hypoxia-Inducible Factor-1{alpha} (HIF-1{alpha}) and
Stimulates the Synthesis of Vascular Endothelial Growth Factor (VEGF).
Nasimuzzaman M, et al. J Virol. 2007 Jul 11; [Epub ahead of print]
Utilization
of RNA polymerase I promoter and terminator sequences to develop a DNA
transfection system for the study of hepatitis C virus internal ribosomal
entry site-dependent translation. Oem JK, et al. J Clin Virol. 2007 Jul
12; [Epub ahead of print].
Diffusion-weighted
magnetic resonance imaging for the assessment of fibrosis in chronic
hepatitis C. Lewin M, et al. Hepatology. 2007 Jul 30; [Epub ahead of
print]
Evidence
for cellular uptake of recombinant hepatitis C virus non-enveloped
capsid-like particles. Tsitoura P, et al. FEBS Lett. 2007 Jul 27; [Epub
ahead of print].
Deletion
of N-glycosylation sites of hepatitis C virus envelope protein E1 enhances
specific cellular and humoral immune responses. Liu M, et al Vaccine. 2007
Jul 23; [Epub ahead of print].
Hepatitis
C Virus p7 Protein Is Crucial for Assembly and Release of Infectious
Virions. Steinmann E, et al. PLoS Pathog. 2007 Jul 20;3(7):e103 [Epub
ahead of print]
Efficient
regulation of viral replication by siRNA in a non-human primate surrogate
model for hepatitis C. Yokota T, et al Biochem Biophys Res Commun. 2007
Jul 16; [Epub ahead of print]
Proteomic
profiling of human liver biopsies: Hepatitis C virus-induced fibrosis and
mitochondrial dysfunction. Diamond DL, et al Hepatology. 2007 Jul 25;
[Epub ahead of print]
Amino
acid substitutions in the hepatitis C virus core region are the important
predictor of hepatocarcinogenesis. Akuta N et al. Hepatology. 2007 Jul 26;
[Epub ahead of print].
Involvement
of PI3K in HCV-related lymphoproliferative disorders. Alisi A, et al. J
Cell Physiol. 2007 Jul 24; [Epub ahead of print]
Cre-estrogen
receptor-mediated hepatitis C virus structural protein expression in mice.
Tumurbaatar B, et al. J Virol Methods. 2007 Jul 10; [Epub ahead of print]
Liver
disease in hepatitis C virus carriers identified at blood donation and
their outcomes with or without interferon treatment: Study on 1019
carriers followed for 5-10 years. Mizui M, et al. Hepatol Res. 2007 Jul
11; [Epub ahead of print]
Myxovirus-1
and protein kinase haplotypes and fibrosis in chronic hepatitis C virus.
Yee LJ, et al. Hepatology. 2007 Jul;46(1):74-83.
Cellular
cofactors affecting hepatitis C virus infection and replication. Randall
G, et al. Proc Natl Acad Sci U S A. 2007 Jul 31;104(31):12884-9. Epub 2007
Jul 6.
Bile
Acids Promote the Expression of Hepatitis C Virus in Replicon-Harboring
Cells. Chang KO, et al. J Virol. 2007 Jul 3; [Epub ahead of print]
Clearance
and persistence of hepatitis C virus in a Tunisian population: association
with HLA class I and class II. Ksiaa L, et al. Viral Immunol. 2007
Summer;20(2):312-9.
T
cell dysfunction by hepatitis C virus core protein involves PD-1/PDL-1
signaling. Yao ZQ, et al. Viral Immunol. 2007 Summer;20(2):276-87.
Chronic
inflammation associated with hepatitis C virus infection perturbs hepatic
transforming growth factor beta signaling, promoting cirrhosis and
hepatocellular carcinoma. Matsuzaki K, et al. Hepatology. 2007
Jul;46(1):48-57.
Insulin
resistance and liver injury in hepatitis C is not associated with
virus-specific changes in adipocytokines. Cua IH, et al. Hepatology. 2007
Jul;46(1):66-73.
Triphasic
decline of hepatitis C virus RNA during antiviral therapy. Dahari H, et
al. Hepatology. 2007 Jul;46(1):16-21.
Analysis
of the relationship between cytokine secretion and proliferative capacity
in hepatitis C virus infection. Semmo N, et al. J Viral Hepat. 2007
Jul;14(7):492-502.
Somatic
hypermutation and mRNA expression levels of the BCL-6 gene in patients
with hepatitis C virus-associated lymphoproliferative diseases. Hofmann
WP, et al. J Viral Hepat. 2007 Jul;14(7):484-91.
Hepatitis
C virus protein expression causes calcium-mediated mitochondrial
bioenergetic dysfunction and nitro-oxidative stress. Piccoli C, et al.
Hepatology. 2007 Jul;46(1):58-65.
HIV/HCV Co-Infection
Adding
HCV Treatment to HIV Treatment in HIV-HCV Coinfected Patients: The Impact
on the Different Dimensions of Fatigue and Self-Reported Side Effects.
Marcellin F, et al. J Pain Symptom Manage. 2007 Jul 4; [Epub ahead of
print]
Dendritic
cell function during chronic hepatitis C virus and HIV-1 infection. Fan Z,
et al. Clin Vaccine Immunol. 2007 Jul 18; [Epub ahead of print]
Hepatotoxicity
of Antiretroviral Drugs Is Reduced after Successful Treatment of Chronic
Hepatitis C in HIV-Infected Patients. Labarga P, et al.. J Infect Dis.
2007 Sep 1;196(5):670-6. Epub 2007 Jul 13.
Prevalence
of HIV and hepatitis C virus infections among inmates of Ontario remand
facilities. Calzavara L, et al. CMAJ. 2007 Jul 31;177(3):257-61.
Prevalence
of HIV and hepatitis C virus infections among inmates of Quebec provincial
prisons.
Clinicoimmunological
Progression and Response to Treatment of Long-Term Nonprogressor
HIV-Hepatitis C Virus-Coinfected Patients. Castro P, et al. AIDS Res Hum
Retroviruses. 2007 Jul;23(7):863-7.
Clinical
progression of hepatitis C virus-related chronic liver disease in human
immunodeficiency virus-infected patients undergoing highly active
antiretroviral therapy. Pineda JA, et al. Hepatology. 2007 Jul 20; [Epub
ahead of print]
Hepatitis
C Infection Is Associated with Lower Lipids and High-Sensitivity
C-Reactive Protein in HIV-Infected Men. Floris-Moore M, et al. AIDS
Patient Care STDS. 2007 Jul;21(7):479-91.
Risk
Factors for Grade 3-4 Liver Enzyme Elevation in HIV and Hepatitis C
Coinfected Patients on Combination Antiretroviral Therapy. Chihrin S, et
al. AIDS Patient Care STDS. 2007 Jul;21(7):469-78.
Risk
factors and algorithms to identify hepatitis C, hepatitis B, and HIV among
Georgian tuberculosis patients. Kuniholm MH, et al Int J Infect Dis. 2007
Jul 20; [Epub ahead of print]
Chronic
hepatitis B and other correlates of spontaneous clearance of hepatitis C
virus among HIV-infected people with hemophilia. Melendez-Morales L, et
al. AIDS. 2007 Jul 31;21(12):1631-1636.
Determinants
of nevirapine hypersensitivity and its effect on the association between
hepatitis C status and mortality in antiretroviral drug-naive HIV-positive
patients. Phillips E, et al. AIDS. 2007 Jul 31;21(12):1561-1568.
The
treatment of chronic hepatitis C in HIV-infected patients: a
meta-analysis. Kim AI, et al. HIV Med. 2007 Jul;8(5):312-21.
The
impact of chronic hepatitis C on health-related quality of life in
homeless and marginally housed individuals with HIV. Tsui JI, et al. AIDS
Behav. 2007 Jul;11(4):603-10.
complementary and alternative therapies
Development
of a tomato-based food for special medical purposes as therapy adjuvant
for patients with HCV infection. Vitaglione P, et al. Eur J Clin Nutr.
2007 Jul;61(7):906-15. Epub 2006 Dec 20
Effect
of micronutrients and iron supplementation on hemoglobin, iron status, and
plasma hepatitis C and HIV RNA levels in female injection drug users: a
controlled clinical trial. Semba RD, et al. J Acquir Immune Defic Syndr.
2007 Jul 1;45(3):298-303.
miscellaneous works
Quality
of life after liver transplantation for hepatitis C infection. Dudley T,
et al. Qual Life Res. 2007 Jul 31; [Epub ahead of print]
Overview
of research on health-related quality of life in patients with chronic
liver disease. Gutteling JJ, et al Neth J Med. 2007 Jul-Aug;65(7):227-34.
Health
services for HIV/AIDS, HCV, and sexually transmitted infections in
substance abuse treatment programs. Brown LS Jr, et al. Public Health Rep.
2007 Jul-Aug;122(4):441-51.
Living
With the Stigma of Hepatitis C. Butt G, et al. West J Nurs Res. 2007 Jul
13; [Epub ahead of print]
Harm
reduction, hepatitis C and opioid pharmacotherapy: an opportunity for
integrated hepatitis C virus-specific harm reduction. Hallinan R, et al.
Drug Alcohol Rev. 2007 Jul;26(4):437-43.
Productivity
improvements in hepatitis C treatment: impact on efficacy, cost,
cost-effectiveness and quality of life. Lidgren M, et al. Scand J
Gastroenterol. 2007 Jul;42(7):867-77.
Transient
elastography for patients with chronic hepatitis B and C virus infection:
Non-invasive, quantitative assessment of liver fibrosis. Ogawa E, et al.
Hepatol Res. 2007 Jul 1; [Epub ahead of print]
Directly
observed therapy for the treatment of hepatitis C virus infection in
current and former injection drug users. Grebely J, et al . J
Gastroenterol Hepatol. 2007 Jul 20; [Epub ahead of print]
Frequency
of very low HCV viremia detected by a highly sensitive HCV-RNA assay.
Fytili P, et al. J Clin Virol. 2007 Aug;39(4):308-11. Epub 2007 Jul 12.
FIB-4:
an inexpensive and accurate marker of fibrosis in HCV infection.
comparison with liver biopsy and fibrotest. Vallet-Pichard A, et al.
Hepatology. 2007 Jul;46(1):32-6.
Seroprevalence
of hepatitis C virus and hepatitis B virus among San Francisco injection
drug users, 1998 to 2000. Tseng FC, et al. Hepatology. 2007 Jul 26; [Epub
ahead of print]
|
